Avalo Therapeutics AVTX
NASDAQ AVTX
$14.95 -0.38 (-2.48%)
At close: Oct 1, 2026 · 4:00 PM EDT

Avalo Therapeutics (AVTX) Preferred Stock Liabilities (2014 - 2024)

Updated

Avalo Therapeutics (AVTX) recorded Preferred Stock Liabilities of $1.66 million in Q3 2024, down 85.5% from the prior quarter.

Analysis

Avalo Therapeutics (AVTX) Preferred Stock Liabilities (2014 - 2024) Analysis & Trends

At the end of FY2014, Avalo Therapeutics reported Preferred Stock Liabilities of $28.35 million, down 28.6% from FY2013.

  • Across earlier years, Preferred Stock Liabilities came in at $39.71 million in FY2013.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Avalo Therapeutics 668.42 Mn 668.42 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2024 1.66 Mn
Jun 30, 2024 11.46 Mn
Mar 31, 2024 11.46 Mn
Sep 30, 2015 28.35 Mn
Dec 31, 2014 28.35 Mn
API Access

Avalo Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=AVTX&period=max&api_key=YOUR_API_KEY